Table 1.
CB1/CB2 cannabinoid receptor binding, molecular targets and therapeutic potential of CBD derivatives.
| Compounds | CB1R Ki [nM] | CB2R Ki [nM] | Reference | Other targets | Therapeutic potential | Reference |
|---|---|---|---|---|---|---|
| (-)-CBD | >10000 | >10000 | Bisogno et al., 2001 | NAM-CB1; FABPs; GPR55; GPR18; 5-HT1A; 5-HT2A; 5-HT3A; GlyR A1A; PPARγ; GABAA, TRPs | Neuroprotection; epilepsy; anxiety; psychosis; inflammation | Fasinu et al., 2016; Morales et al., 2017 |
| (-)-CBDA | COX-2; TRPA1; DAGLα | Inflammation; cancer; bacteria | Appendino et al., 2008; Takeda et al., 2008, 2012; De Petrocellis et al., 2011 | |||
| (-)-CBDV | 14711 ± 5734 | 574.2 ± 146 | Rosenthaler et al., 2014 | GPR55; TRPA1; CYP1A1 | Convulsion; epilepsy | De Petrocellis et al., 2011; Anavi-Goffer et al., 2012; Hill et al., 2012, 2013; Yamaori et al., 2013; Rosenthaler et al., 2014; Jones and Whalley, 2015 |
| Machaeridol B | - | - | - | Plasmodium falciparum; Leishmania donovani | Muhammad et al., 2003 | |
| Ferruginene C | NR | Weak | Seephonkai et al., 2011 | TRPA1 | Cancer | Seephonkai et al., 2011 |
| (-)-7-OH-CBD | >10000 | >10000 | Bisogno et al., 2001 | - | ||
| (+)-7-OH-CBD | 5.3 ± 0.5 | 101.0 ± 5.1 | Fride et al., 2004 | - | - | |
| (-)-7-COOH-CBD | >10000 | >10000 | Bisogno et al., 2001 | - | - | |
| (+)-7-COOH-CBD | 13.2 ± 0.4 | 312.8 ± 15.8 | Fride et al., 2004 | - | - | |
| CBE | - | - | CYP1A1 | - | Yamaori et al., 2013 | |
| (+)-CBD | 842 ± 36 | 203 ± 16 | Bisogno et al., 2001 | - | - | |
| H2-CBD | >1000 | - | Ben-Shabat et al., 2006 | - | Inflammation | Ben-Shabat et al., 2006 |
| H4-CBD | 145 | - | Ben-Shabat et al., 2006 | - | Inflammation | Ben-Shabat et al., 2006 |
| HU-444 | >10000 | >10000 | Haj et al., 2015 | - | Inflammation | Haj et al., 2015 |
| HU-446 | ∼1000 | >10000 | Kozela et al., 2015 | - | Inflammation | Haj et al., 2015 |
| HU-465 | 76.7 ± 58 | 12.1 ± 2.3 | Kozela et al., 2015 | - | Inflammation | Haj et al., 2015 |
| (-)-DMH-CBD | >10000 | >1000 | Bisogno et al., 2001 | - | Anxiety; pain; inflammation; cancer | Burstein, 2015; Juknat et al., 2016 |
| (+)-DMH-CBD | 17.4 ± 1.8 | 211 ± 23 | Bisogno et al., 2001 | - | - | |
| (-)-7-OH-DMH-CBD | >4000 | 671 ± 12 | Bisogno et al., 2001 | TRPV1, opioid, α2-AR | - | Fride et al., 2005; Pertwee et al., 2005 |
| (+)-7-OH-DMH-CBD | 2.5 ± 0.03 | 44.0 ± 3.1 | Bisogno et al., 2001 | - | - | |
| (-)-7-COOH-DMH-CBD (HU-320) | > 1000 | >4000 | Bisogno et al., 2001 | - | Inflammation, immunosuppression | Sumariwalla et al., 2004 |
| (+)-7-COOH-DMH-CBD | 5.8 ± 0.7 | 155.5 ± 5.3 | Fride et al., 2004 | - | - | |
| H2-DMH-CBD | 124 | - | Ben-Shabat et al., 2006 | - | ||
| H4-DMH-CBD | 17 | - | Ben-Shabat et al., 2006 | - | ||
| HU-308 | >10000 | 22.7 ± 3.9 | Hanus et al., 1999 | - | Inflammation; hepatic ischemia; osteoporosis; pain | Ofek et al., 2006; Rajesh et al., 2007a,b; Burstein, 2015 |
| (-)-CBDD | >10000 | >10000 | Hanus et al., 2005 | 15-LOX | Atherosclerosis, body weight regulation | Takeda et al., 2009, 2011, 2015 |
| (+)-CBDD | >10000 | >10000 | Hanus et al., 2005 | - | - | |
| (-)-DMH-CBDD | >10000 | >10000 | Hanus et al., 2005 | - | - | |
| (+)-DMH-CBDD | >10000 | <10000 | Hanus et al., 2005 | - | - | |
| KLS-13019 | - | - | Neuroprotection | Kinney et al., 2016 | ||
| HUF-101 | - | - | - | Anxiety; depression, psychosis; convulsion | Breuer et al., 2016 | |
| CBD-aldehyde-diacetate | - | - | - | Convulsion | Carlini et al., 1975 | |
| 6-Oxo-CBD-diacetate | - | - | - | Convulsion | Carlini et al., 1975 | |
| 6-OH-CBD-triacetate | - | - | - | Convulsion | Carlini et al., 1975 | |
| 9-OH-CBD-triacetate | - | - | - | Convulsion | Carlini et al., 1975 | |
| HU-331 | NR | NR | Kogan et al., 2004 | Topoisomerase IIα; Caspases; ROS; PARP | Cancer | Kogan et al., 2004, 2007; Petronzi et al., 2013; Regal et al., 2014 |
| CBD-Q (V) | - | - | PPARγ | Neuroprotection | Appendino et al., 2015 | |
| CBD-Q (VIII) | - | - | PPARγ | Neuroprotection | Appendino et al., 2015 | |
| Abn-CBD | - | - | GPR55; GPR18 | Vasodilatation; bacteria; diabetes; colitis | Johns et al., 2007; Ryberg et al., 2007; Appendino et al., 2008; Console-Bram et al., 2014; Krohn et al., 2016; McKillop et al., 2016 | |
| O-1602 | NR | NR | GPR55; GPR18 | Central nervous system; metabolism | Johns et al., 2007; Romero-Zerbo et al., 2011; Ashton, 2012; Console-Bram et al., 2014 | |
| CBG | 897 ± 596 | 153 ± 42 | Rosenthaler et al., 2014 | α2-AR; TRP; COX-1; COX-2; 5-HT1A | Bacteria; bowel inflammation; depression | Appendino et al., 2008; Cascio et al., 2010; El-Alfy et al., 2010; De Petrocellis et al., 2011; Ruhaak et al., 2011; Borrelli et al., 2013; Rosenthaler et al., 2014 |
| Cannabimovone | >10000 | >10000 | Taglialatela-Scafati et al., 2010 | TPRV1 | - | Taglialatela-Scafati et al., 2010 |
NR, no response.